<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721470</url>
  </required_header>
  <id_info>
    <org_study_id>6615-18-12-2016</org_study_id>
    <nct_id>NCT04721470</nct_id>
  </id_info>
  <brief_title>Combined Therapy for Hepatocellular Carcinoma &gt;3-&lt;5 cm</brief_title>
  <official_title>Combined Therapy With Conventional Trans-arterial Chemoembolization (cTACE) and Microwave Ablation (MWA) for Hepatocellular Carcinoma &gt;3-&lt;5 cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of combined therapy with&#xD;
      conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only&#xD;
      TACE or MWA for treatment of hepatocellular carcinoma (HCC) &gt;3-&lt;5 cm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to compare the safety and efficacy of combined therapy with conventional&#xD;
      transarterial chemoembolization (cTACE)+microwave ablation (MWA) versus only TACE or MWA for&#xD;
      treatment of hepatocellular carcinoma (HCC) &gt;3-&lt;5 cm.&#xD;
&#xD;
      This randomized controlled trial screened 278 patients with HCC &gt;3-&lt;5 cm. Patients were&#xD;
      randomized into three groups: 90 underwent TACE (Group 1); 95 underwent MWA (Group 2); and 93&#xD;
      underwent combined therapy (Group 3). Patients were followed-up with contrast-enhanced CT or&#xD;
      MRI. Images were evaluated and compared for treatment response and adverse events based on&#xD;
      modified response evaluation criteria in solid tumor. Serum alpha-fetoprotein (AFP)&#xD;
      concentration was measured at baseline and during every follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">October 20, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were randomized into three groups: 90 underwent TACE (Group 1); 95 underwent MWA (Group 2); and 93 underwent combined therapy (Group 3).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to three years after procedure</time_frame>
    <description>Images were evaluated and compared for adverse events. The adverse events were recorded and classiﬁed following the guidelines of the Society of Interventional Radiology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Response</measure>
    <time_frame>One month</time_frame>
    <description>Tumor response was evaluated by CECT or dynamic MRI based on the modified response evaluation criteria in solid tumor (m-RECIST) established by the American Association for the Study of Liver Diseases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>12 months after procedure</time_frame>
    <description>The recurrence rate was measured in relation to management lines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall mortality rate</measure>
    <time_frame>Three years after procedure</time_frame>
    <description>The mortality rate was measured in relation to management lines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Three years after procedure</time_frame>
    <description>The progression-free survival was measured in relation to management lines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AFP variation rate</measure>
    <time_frame>Baseline and 1-2 months after procedure</time_frame>
    <description>The AFP variation rate (ΔAFP) was defined as the percentage of change between the AFP concentration at baseline and the postprocedure AFP concentration after 1-2 months as shown in the following equation:&#xD;
ΔAFP (%) = [(AFPbaseline-AFPpostprocedure) /AFPbaseline] ×100%</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Combined therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing combined therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing Transarterial chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microwave ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing Microwave ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined therapy</intervention_name>
    <description>Patients undergoing combined therapy</description>
    <arm_group_label>Combined therapy</arm_group_label>
    <other_name>Transarterial chemoembolization + Microwave ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave ablation</intervention_name>
    <description>Patients undergoing Microwave ablation</description>
    <arm_group_label>Microwave ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial chemoembolization</intervention_name>
    <description>Patients undergoing Transarterial chemoembolization</description>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Solitary HCC &gt;3-&lt;5 cm&#xD;
&#xD;
          2. Absence of extra-hepatic metastases&#xD;
&#xD;
          3. Absence of a history of encephalopathy or refractory ascites&#xD;
&#xD;
          4. Child-Pugh class A or B cirrhosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Poor patient compliance&#xD;
&#xD;
          2. Child-Pugh class C cirrhosis&#xD;
&#xD;
          3. Severe coagulation disorders&#xD;
&#xD;
          4. Portal vein thrombosis&#xD;
&#xD;
          5. Renal impairment (6) previous local ablation therapy of HCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad A Basha, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zagazig University, Egypt</affiliation>
  </overall_official>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Mohammad Abd Alkhalik Basha</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Combined therapy; hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

